Loading...
Market
What will be the next step in MariTide's development by end of 2025?
2
Resolution / Starting Odds
Phase 3 trials initiated • 25%
Partnership with another company • 25%
Drug shelved or development paused • 25%
Other developments • 25%
Amgen's official announcements and industry reports
Story
Amgen's MariTide Achieves 20% Weight Loss in Phase 2; Shares Drop 12%
Nov 26, 2024, 12:20 PM
Amgen Inc. announced that its experimental obesity drug, MariTide (maridebart cafraglutide), a GLP-1/GIPR agonist, demonstrated up to 20% average weight loss at 52 weeks in a Phase 2 study involving people with obesity or overweight. In patients with Type 2 diabetes, the drug achieved approximately 17% weight loss and lowered HbA1c levels by 2.2 points. The study showed no weight-loss plateau and reported a gastrointestinal dropout rate of less than 8%. Amgen scheduled a conference call at 8 am ET to discuss the data. Despite the promising results, Amgen's stock price fell by up to 12% in premarket trading, indicating that the data may have fallen short of market expectations.
View original story
Similar markets
No new concerns • 25%
Minor concerns • 25%
Moderate concerns • 25%
Major concerns • 25%
Exceeds forecasts • 25%
Meets forecasts • 25%
Below forecasts • 25%
Significantly below forecasts • 25%
Less than $250M • 33%
$250M to $500M • 33%
More than $500M • 34%
Initiate clinical trial • 25%
Secure additional funding • 25%
Enter partnership • 25%
Other • 25%
Yes • 50%
No • 50%
Cryptocurrency • 25%
Precious Metals • 25%
Real Estate • 25%
Other • 25%
Video Interviewing • 25%
AI-Powered Resume Screening • 25%
Skill Assessment Tests • 25%
Other • 25%
Initiation of Phase 1 clinical trials • 25%
Publication of preclinical study results • 25%
Securing additional funding • 25%
Partnership with a major pharmaceutical company • 25%